Transgene update from the previously mentioned ESMO congress (Madrid):
* Presents additional positive clinical data from phase 2b part of time trial with TG4010 at European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain
* Announces statistically significant difference in progression-free survival continuing to be seen in non-squamous patient population
* Announces promising overall survival data, notably in subgroups of interest for the upcoming phase 3 trial
http://www.reuters.com/article/2014/09/29/transgene-brief-idUSFWN0RR00R20140929
Transgene update from the previously mentioned ESMO congress...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
